丹参酮ⅡA磺酸钠治疗急性脑出血的安全性分析  

Safety analysis of tanshinone Ⅱ A sodium sulfonate in treatment of acute cerebral hemorrhage

作　　者：程艳[1] 封丽芳[2] 郑玉明[3] 代雪梅[4] 

机构地区：[1]山东省滨州市人民医院神经内科,256610 [2]山东省滨州市人民医院家庭病床科,256610 [3]山东省滨州市人民医院急诊科,256610 [4]山东省滨州市人民医院体检科,256610

出　　处：《中国医师进修杂志》2014年第16期17-20,共4页Chinese Journal of Postgraduates of Medicine

摘　　要：目的 探讨急性脑出血应用丹参酮ⅡA磺酸钠的安全性.方法 根据治疗方法将172例急性脑出血患者分为丹参酮治疗组84例（丹参酮ⅡA磺酸钠＋传统治疗）和常规治疗组88例（传统治疗）.分别于治疗前、治疗2周后及治疗4周后对患者的安全性（包括神经功能缺损评分、不良反应、再出血发生率及病死率等）进行判定.结果 丹参酮治疗组在治疗2,4周后中国脑卒中患者临床神经功能缺损程度（CSS）评分均明显低于常规治疗组[（13.2±4.3）分比（17.4±5.6）分,（8.7±3.5）分比（12.8±4.6）分],差异有统计学意义（t=5.498,6.556,P＜0.01）;丹参酮治疗组总有效率明显高于常规治疗组[83.3％（70/84）比65.9％ （58/88）],差异有统计学意义（x2=6.854,P＜0.01）;丹参酮治疗组使用丹参酮ⅡA磺酸钠后,有5例出现轻微皮疹,3例出现恶心、呕吐,给予对症处理后均好转,观察期间未见其他药物不良反应.丹参酮治疗组的病死率、再出血率均低于常规治疗组,但差异无统计学意义（P＞0.05）.结论 急性脑出血早期应用丹参酮ⅡA磺酸钠治疗疗效显著,临床应用过程中安全、可靠,值得我们在临床中进行推广.Objective To investigate the safety of tanshinone Ⅱ A sodium sulfonate in treatment of acute cerebral hemorrhage.Methods One hundred and seventy-two patients with acute cerebral hemorrhage were divided into tanshinone treatment group with 84 cases （tanshinone Ⅱ A sodium sulfonate ＋ traditional treatment） and traditional treatment group with 88 cases （traditional treatment） according to the method of treatment.The safety （including neural function defect,adverse reactions,rebleeding rate and mortality and so on） were determined before treatment,and 2,4 weeks after treatment.Results The chinese stroke scale （CSS） scores in tanshinone treatment group after treatment of 2,4 weeks were lower than those in traditional treatment group [（13.2 ± 4.3） scores vs.（17.4 ± 5.6） scores,（8.7 ± 3.5） scores vs.（12.8 ± 4.6） scores],there were significant differences （t =5.498,6.556,P 〈 0.01）.The total effective rate in tanshinone treatment group was significantly higher than that in treatment group [83.3 % （70/84） vs.65.9 % （58/88）],there was significant difference （x2 =6.854,P 〈 0.01）.After treatment with tanshinone Ⅱ A sodium sulfonate in tanshinone treatment group,5 cases of mild skin rash,3 cases of nausea,vomiting,to turn for the better after symptomatic treatment.There was not other adverse reactions in the observation period.The mortality,rebleeding rate in tanshinone treatment group were lower than those in traditional treatment group,but there were no significant differences （P 〉 0.05）.Conclusions Early application of tanshinone Ⅱ A sulfonate treatment in acute cerebral hemorrhage has significantly efficacy,in the process of the clinical application is safe amd reliable.It is worthy of clinical popularization.

关 键 词：脑出血 丹参 安全性 

分 类 号：R743.34[医药卫生—神经病学与精神病学]